

ARE YOU ONE OF THE MILLIONS OF WOMEN WHO HAVE FACED BREAST CANCER?



IF YOU'RE CURRENTLY CANCER-FREE, CONSIDER OUR RESEARCH STUDY.

A study is being conducted to evaluate whether an investigational drug can reduce the risk of previously diagnosed HER-2 positive breast cancer from returning after treatment with trastuzumab. This study will enroll women who have erbB-2 (HER-2) positive breast cancer and have completed a course of prior trastuzumab treatment.

You may be able to participate in this study if you:

- Have erbB-2 (HER-2) positive breast cancer
- Have completed a course of prior trastuzumab treatment
- Have a diagnosis of early stage (I, II, III, IIIB, IIIC) primary breast cancer
- Are not currently receiving chemotherapy, radiation therapy, immunotherapy or biotherapy for breast cancer

Study participation lasts for up to approximately 5 years. All office visits, study-related medical evaluations, and study drug will be provided to participants at no cost.

For more information about this study, please contact:

Midwest Center for

Hematology/Oncology, SC

Cancer Care with Compassion.

Adjacent to Silver Cross Hospital
1301 Copperfield Ave, Suite 105 Joliet
(815) 740-1400

Find out more on our website
www.mwcho.com